Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair–deficient or microsatellite instability–high primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Résumé fourni par la source

Background: In Part 1 of the phase 3 RUBY trial (NCT0-3981796), dostarlimab+carboplatin-paclitaxel (CP) demonstrated statistically significant and clinically meaningful improvements in progression- free (PFS) and overall survival (OS) compared with CP alone among patients with primary advanced or recurrent endometrial cancer (pA/R EC). Here, we report updated efficacy and safety data with 4 years of follow-up in patients with mismatch repair-deficient/microsatellite instability-high (dMMR/ MSI-H) pA/R EC. In addition, complementary conditional survival analyses (cOS/cPFS) are presented to provide clinically relevant, prognostic insights into long-term survival potential for patient counseling. Objectives: Describe long-term progression-free survival and overall survival in patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in Part 1 of the RUBY trial. Describe the probability of long-term survival using conditional overall survival, a tool that may aid clinicians in counseling patients on their likelihood of long-term survival in the era of immunotherapy in endometrial cancer. Methods: Patients were randomized 1:1 to receive dostarlimab+ CP (n=53) or placebo+CP (n=65) every 3 weeks every 3 weeks (Q3W) (6 cycles) followed by dostarlimab or placebo monotherapy Q6W for up to 3 years or until disease progression. At median follow-up of 55.6 months, descriptive analyses of OS and PFS and post-hoc analyses of cOS and cPFS were conducted in the dMMR/MSI-H pA/R EC population. Results: Dostarlimab+CP demonstrated sustained OS (hazard ratio (HR), 0.34) and PFS (HR, 0.30) benefits at the 4-year analysis versus (vs) placebo+CP; only 4 additional progression events occurred during 2.5 years of additional follow-up since the first interim analysis. Four-year PFS rates of 57.9% vs 15.7% were consistent with reported 2-year PFS rates of 61.4% vs 15.7% for dostarlimab+CP vs placebo+ CP, respectively. Median OS was not reached (NR) at 4 years for dostarlimab+CP arm vs 32.8 months for placebo+CP; dostarlimab+CP resulted in a 4-year OS rate of 72.8% vs 40.3% for placebo+CP. Median duration of response (DOR) was NR for dostarlimab+CP and 4.8mo for placebo+CP; 4-year DOR rate was 54.8% for dostarlimab+ CP and 10.6% for placebo+CP. cOS analyses revealed the probability of remaining alive for an additional year increased with each subsequent year of survival. Patients alive and progression-free at 1-year had an almost 97% probability of remaining progression-free at 3 years (additional 2 years). Similar trends were observed at 2-year and 3-year cOS and at 2-year cPFS. No new safety signals were observed with additional follow-up. Conclusions: Substantial and unprecedented long-term survival benefits were demonstrated with dostarlimab+CP vs placebo+CP in patients with dMMR/MSI-H pA/R EC at 4 years. Dostarlimab+CP remains the only combination of immunotherapy and chemotherapy to demonstrate statistically significant and clinically meaningful OS benefits. Conditional survival estimates indicated that nearly all patients who remained alive and progression-free with dostarlimab+CP at 1 year remained so at 3 years, providing a powerful tool for patient counseling. Together, these data reinforce the use of dostarlimab+CP as standard-of-care and offer the potential for curative intent for patients with pA/R dMMR/MSI-H EC. Funding: GSK. Prior Presentations: Presented at the Society of Gynecological Oncology (SGO) Annual Meeting on Women’s Cancer 2026, April 10–13, San Jaun, Puerto Rico.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.